Ted Driscoll was named director at Claremont Creek Ventures and will lead the digital healthcare team. He was previously a technology partner. Driscoll has sourced and led four healthcare deals at Claremont: GigaGen, GeneWeave Bioscience, Zipline Medical and Cureus.
CLAREMONT CREEK VENTURES PROMOTES TED DRISCOLL, PhD TO DIRECTOR
Driscoll to lead the Digital Healthcare Team
Former CCV Technology Partner Praised for Technology Savvy and Deal Sourcing Abilities
OAKLAND, CA (July 24, 2012) – Ted Driscoll, formerly a technology partner at Claremont Creek Ventures, has been promoted to Director and will lead the Digital Healthcare team at the same venture firm. Claremont Creek Ventures is a seed and early-stage investor in digital healthcare and energy technology. Driscoll’s new appointment is effective immediately.
In his tenure at Claremont Creek Ventures, Driscoll has sourced and led four healthcare deals: GigaGen, GeneWeave Bioscience, Zipline Medical and Cureus.
“I have worked with Ted for the last 25 years starting with Identix. He has always been a stellar performer and that’s why I brought him to CCV. Ted is a phenomenal asset and has been of enormous value since his arrival,” said Randy Hawks, a co-founder and managing director of Claremont Creek Ventures. “Entrepreneurs praise his understanding of technology and his willingness to give hands-on support to every investment in the very early stages in which we invest,” Hawks said. “This promotion is well deserved.”
In addition to Driscoll, CCV’s digital healthcare executives include Brad Webb, PhD in molecular biology and a venture partner. The team also consists of associate Brian Berger, MD. Driscoll has worked at Claremont Creek Ventures since 2006. Ted’s investment portfolio currently includes the companies Geneweave Biosciences, GigaGen, Natera, Tibion, and Zipline Medical. He is also an advisor to seed stage company, Cureus.
Prior to his venture capital experience, Driscoll helped found five successful companies in imaging-related markets. He was founder and CEO of Be Here Technologies, a pioneer in Internet, broadcast and videoconferencing technologies. He served as a division president and chief technology officer of Diasonics, with responsibility for its MRI, ultrasound, digital X-ray, lithotripsy and acoustic ablation areas. Driscoll was also the vice president of engineering and R&D of Identix, now a world leader in fingerprint and face recognition, and the director of R&D at International Imaging Systems, an early pioneer in remote sensing. His research and patents in ultrasound therapy and acoustic hemostasis also led to the founding of Therus, now partnered with Boston Scientific.
Driscoll holds a PhD from Stanford University in digital imaging, master degrees from Harvard University in computer graphics and remote sensing, and a bachelor’s degree from the University of Pennsylvania. Driscoll holds more than 40 patents in image-related fields.
In other personnel developments at Claremont Creek Ventures, John Steuart, a managing director, recently departed from the firm.
About Claremont Creek Ventures
Claremont Creek Ventures is a seed and early-stage venture firm that invests in digital healthcare, energy technology, payments/commerce and online businesses. Utilizing its proprietary life-cycle venturing strategies, the firm partners with entrepreneurs and institutions, including UC Berkeley, Lawrence Livermore Labs, Stanford University and UC Davis. Claremont Creek Ventures has more than $300 million in capital under management in two funds. The firm has 24 portfolio companies with 10 investments in digital healthcare including AssureRX, CellScope, Cureus, Fluxion, Genalyte, GeneWeave Biosciences, GigaGen, Natera, Tibion and Zipline Medical. www.claremontcreek.com